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A B S T R A C T
Background
Opioid drugs, including hydromorphone, are commonly used to treat neuropathic pain, and are considered effective by some profes-
sionals. Most reviews have examined all opioids together. This review sought evidence specifically for hydromorphone, at any dose,
and by any route of administration. Other opioids are considered in separate reviews.
This review is part of an update of a previous review, Hydromorphone for acute and chronic pain that was withdrawn in 2013 because it
needed updating and splitting to be more specific for different pain conditions. This review focuses only on neuropathic pain.
Objectives
To assess the analgesic efficacy of hydromorphone for chronic neuropathic pain in adults, and the adverse events associated with its use
in clinical trials.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), via the CRSO; MEDLINE via Ovid; and EMBASE
via Ovid from inception to 17 November 2015, together with reference lists of retrieved papers and reviews, and two online study
registries.
Selection criteria
We included randomised, double-blind studies of two weeks’ duration or longer, comparing hydromorphone (at any dose, by any route
of administration, or in any formulation) with placebo or another active treatment in chronic neuropathic pain.
Data collection and analysis
Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality.
We did not carry out any pooled analyses. We assessed the quality of the evidence using GRADE (Grading of Recommendations
Assessment, Development and Evaluation).
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Main results
Searches identified seven publications relating to four studies. We excluded three studies. One post hoc (secondary) analysis of a
study published in four reports assessed the efficacy of hydromorphone in neuropathic pain, satisfied our inclusion criteria, and was
included in the review. The single included study had an enriched enrolment, randomised withdrawal design with 94 participants
who were successfully switched from oral morphine to oral hydromorphone extended release (about 60% of those enrolled). These
participants were then randomised to continuing hydromorphone for 12 weeks or tapering down the hydromorphone dose to placebo.
The methodological quality of the study was generally good, but we judged the risk of bias for incomplete outcome data as unclear,
and for study size as high.
Since we identified only one study for inclusion, we were unable to carry out any analyses. The included study did not report any of
our prespecified primary outcomes, which relate to the number of participants achieving moderate or substantial levels of pain relief.
It did report a slightly larger increase in average pain intensity for placebo in the randomised withdrawal phase than for continuing
with hydromorphone. It also reported the number of participants who withdrew due to lack of efficacy in the randomised withdrawal
phase, which may be an indicator of efficacy. However, in addition to using an enriched enrolment, randomised withdrawal study
design, there was an unusual choice of imputation methods for withdrawals (about 50% of participants); the evidence was of very low
quality and inadequate to make a judgement on efficacy. Adverse events occurred in about half of participants with hydromorphone,
the most common being constipation and nausea. A similar proportion of participants experienced adverse events with placebo, the
most common being opioid withdrawal syndrome (very low quality evidence). Most adverse events were mild or moderate in intensity.
One in eight participants withdrew while taking hydromorphone during the conversion and titration phase, despite participants being
opioid-tolerant (very low quality evidence).
We downgraded the quality of the evidence to very low because there was only one study with few participants, it did not report
clinically useful efficacy outcomes, and it was a post hoc analysis.
Authors’ conclusions
There was insufficient evidence to support or refute the suggestion that hydromorphone has any efficacy in any neuropathic pain
condition.
P L A I N L A N G U A G E S U M M A R Y
Hydromorphone for neuropathic pain in adults
Bottom line
There is no good evidence to support or refute the suggestion that hydromorphone works in any neuropathic pain condition.
Background
Neuropathic pain is pain coming from damaged nerves. It is different from pain messages that are carried along healthy nerves from
damaged tissue (for example, a fall or cut, or arthritic knee). Neuropathic pain is often treated by different medicines (drugs) to those
used for pain from damaged tissue, which we often think of as painkillers. Medicines that are sometimes used to treat depression or
epilepsy can be very effective in some people with neuropathic pain. But sometimes opioid painkillers are used to treat neuropathic
pain.
Opioid painkillers are drugs like morphine. Morphine is derived from plants, but many opioids are also made by chemical synthesis
rather than being extracted from plants. Hydromorphone is one of these synthetic opioids. It is available in numerous countries for use
as a painkiller, and can be given by mouth or by injection.
This review is part of an update of a previous review, Hydromorphone for acute and chronic pain that was withdrawn in 2013 because it
needed updating and splitting to be more specific for different pain conditions. This review focuses only on neuropathic pain.
Study characteristics
In November 2015, we searched for clinical trials where hydromorphone was used to treat neuropathic pain in adults. We found one
small study that did this and met our requirements for the review. The study had a complicated design. Only a minority of participants
had neuropathic pain, with only 94 in the comparison with placebo. Important pain outcomes were not reported.
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Key results
The study provided no convincing evidence of any benefit for hydromorphone over placebo. Of those people who started taking
hydromorphone, one in eight stopped because of side effects in the first part of the study. The most common side effects were
constipation and nausea, which are typically experienced with opioids.
Quality of the evidence
We rated the quality of the evidence as very low because of the study design, poor reporting of important outcomes, and small numbers
of participants. Very low quality evidence means that we are very uncertain about the results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral hydromorphone compared with placebo for chronic neuropathic pain
Patient or population: adults with chronic neuropathic pain
Settings: community
Intervention: oral hydromorphone ER 12 to 64 mg daily
Comparison: oral placebo
Outcomes Probable outcome with
intervention
Probable outcome with
comparator
RR, NNT, NNTp, or NNH
(95% CI)
No of studies, partici-
pants
Quality of the evidence
(GRADE)
Comments
Substant ial benef it :
≥ 50% reduct ion in pain
PGIC much improved
No data No data No data None - The single study did not
report any useful ef f i-
cacy outcomes
The single trial used
EERW design, with
only 56% entering ran-
domised double-blind
phase, and the study
used unusual criteria
for imputat ion on with-
drawal (49% in ran-
domised double-blind
phase)
Subgroups not bal-
anced by randomisa-
t ion
Moderate benef it :
≥ 30% reduct ion in pain
PGIC much or very
much improved
No data No data No data None - The single study did not
report any useful ef f i-
cacy outcomes
The single trial used
EERW design, with
only 56% entering ran-
domised double-blind
phase, and the study
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used unusual criteria
for imputat ion on with-
drawal (49% in ran-
domised double-blind
phase)
Subgroups not bal-
anced by randomisa-
t ion
Lack of ef f icacy with-
drawal in randomised
double-blind phase
8/ 43 9/ 51 No analysis 1 study
94 part icipants
Very low quality Numbers of events too
small f or sensible anal-
ysis
Adverse event with-
drawal in randomised
double-blind phase
3/ 43 0/ 51 No analysis 1 study
94 part icipants
Very low quality Numbers of events too
small f or sensible anal-
ysis
Serious adverse events None reported specif ically for neuropathic pain - - - -
Deaths None reported - - - -
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI: conf idence interval; EERW: enriched enrolment, randomised withdrawal; ER: extended release; NNT: number needed to
treat for an addit ional benef icial outcome; NNH: number needed to treat for an addit ional harmful outcome; NNTp: number
needed to treat to prevent an addit ional outcome; PGIC: Pat ient Global Impression of Change.
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B A C K G R O U N D
This review is based on a template for reviews of drugs used to
relieve neuropathic pain. The aim is for all reviews to use the
same methods, based on new criteria for what constitutes reliable
evidence in chronic pain (Moore 2010a; Appendix 1).
The review forms part of an update of a previous review, Hydro-
morphone for acute and chronic pain (Quigley 2013), which was
withdrawn in 2013 because of a need to update, and to split the
title to be more specific for different pain conditions. This review
focuses only on neuropathic pain. A protocol for Hydromorphone
for cancer pain has already been published (Bao 2014).
Description of the condition
The 2011 International Association for the Study of Pain defini-
tion of neuropathic pain is “pain caused by a lesion or disease of the
somatosensory system” (Jensen 2011), and based on a definition
agreed at an earlier consensusmeeting (Treede 2008).Neuropathic
pain is a consequence of a pathological maladaptive response of
the nervous system to ’damage’ from a wide variety of potential
causes. It is characterised by pain in the absence of a noxious stim-
ulus and may be spontaneous (continuous or paroxysmal) in its
temporal characteristics or be evoked by sensory stimuli (dynamic
mechanical allodynia where pain is evoked by light touch of the
skin). Neuropathic pain is associated with a variety of sensory loss
(numbness) and sensory gain (allodynia) clinical phenomena, the
exact pattern of which vary between patient and disease, perhaps
reflecting different pain mechanisms operating in an individual
patient and therefore potentially predictive of response to treat-
ment (Demant 2014; Helfert 2015; von Hehn 2012). Pre-clinical
research hypothesises a bewildering array of possible pain mech-
anisms that may operate in people with neuropathic pain, which
largely reflect pathophysiological responses in both the central and
peripheral nervous systems, including neuronal interactions with
immune cells (Baron 2012; Calvo 2012; vonHehn2012).Overall,
the treatment gains in neuropathic pain, to even themost effective
of available drugs, are modest (Finnerup 2015; Moore 2013a),
and a robust classification of neuropathic pain is not yet available
(Finnerup 2013).
Neuropathic pain is usually divided according to the cause of
nerve injury. Theremay bemany causes, but some common causes
of neuropathic pain include diabetes (painful diabetic neuropa-
thy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation
(stump and phantom limb pain), neuropathic pain after surgery
or trauma, stroke or spinal cord injury, trigeminal neuralgia, and
human immunodeficiency virus (HIV) infection. Sometimes the
cause is not known.
Many people with neuropathic pain conditions are significantly
disabledwithmoderate or severe pain formany years. Chronic pain
conditions comprised 5 of the 11 top-ranking conditions for years
lived with disability in 2010 (Vos 2012), and are responsible for
considerable loss of quality of life and employment, and increased
healthcare costs (Moore 2014a).
In systematic reviews, the overall prevalence of neuropathic pain
in the general population is reported to be between 7% and 10%
(van Hecke 2014), and about 7% in a systematic review of stud-
ies published since 2000 (Moore 2014a). In individual countries,
prevalence rates have been reported as 3.3% in Austria (Gustorff
2008), 6.9% in France (Bouhassira 2008), and up to 8% in theUK
(Torrance 2006). Some forms of neuropathic pain, such as PDN
and postsurgical chronic pain (which is often neuropathic in ori-
gin), are increasing (Hall 2008). The prevalence of PHN is likely
to fall if vaccination against the herpes virus becomes widespread.
Estimates of incidence vary between individual studies for partic-
ular origins of neuropathic pain, often because of small numbers
of cases. In primary care in the UK, between 2002 and 2005, the
incidences (per 100,000 person-years’ observation) were 28 (95%
confidence interval (CI) 27 to 30) for PHN, 27 (26 to 29) for
trigeminal neuralgia, 0.8 (0.6 to 1.1) for phantom limb pain, and
21 (20 to 22) for PDN (Hall 2008). Other researchers have esti-
mated an incidence of 4 in 100,000 per year for trigeminal neu-
ralgia (Katusic 1991; Rappaport 1994), and of 12.6 per 100,000
person-years for trigeminal neuralgia and 3.9 per 100,000 per-
son-years for PHN in a study of facial pain in the Netherlands
(Koopman 2009). One systematic review of chronic pain demon-
strated that some neuropathic pain conditions, such as PDN, are
much more common than others, with prevalence rates up to 400
per 100,000 person-years (McQuay 2007).
Neuropathic pain is difficult to treat effectively, with only a mi-
nority of people experiencing a clinically relevant benefit from
any one intervention. A multidisciplinary approach is now advo-
cated, combining pharmacological interventions with physical or
cognitive (or both) interventions. Conventional analgesics such
as paracetamol and nonsteroidal anti-inflammatory drugs are not
thought to be effective, but without evidence to support or refute
that view. Some people may derive some benefit from a topical
lidocaine patch or low-concentration topical capsaicin, although
evidence about benefits is uncertain (Derry 2012; Derry 2014).
High-concentration topical capsaicin may benefit some people
with PHN (Derry 2013). Treatment is often by so-called ’un-
conventional analgesics’ (pain modulators) such as antidepressants
(duloxetine and amitriptyline; Lunn 2014; Moore 2012a; Sultan
2008), or antiepileptics (gabapentin or pregabalin; Moore 2009;
Moore 2014b; Wiffen 2013).
The proportion of people who achieve worthwhile pain relief (typ-
ically at least 50%pain intensity reduction;Moore 2013b) is small,
generally only 10% to 25% more than with placebo, with num-
bers needed to treat for an additional beneficial outcome (NNT)
usually between 4 and 10 (Kalso 2013; Moore 2013a). Neuro-
pathic pain is not particularly different from other chronic pain
conditions in that only a small proportion of trial participants have
a good response to treatment (Moore 2013a).
The current National Institute for Health and Care Excellence
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(NICE) guidance for the pharmacological management of neuro-
pathic pain suggests offering a choice of amitriptyline, duloxetine,
gabapentin, or pregabalin as initial treatment for neuropathic pain
(with the exception of trigeminal neuralgia), with switching if the
first, second, or third drugs tried are not effective or not tolerated
(NICE 2013). This concurs with other recent guidance (Finnerup
2015).
Description of the intervention
Hydromorphone (also known as dihydromorphinone) is a semi-
synthetic derivative of morphine. It is marketed in various coun-
tries under various brand names, commonly known as Dilaudid,
but with other names used in different countries around the world
(including Hydal, Dimorphone, Sophidone LP, Hydrostat, Hy-
dromorfan,Hydromorphan,Hymorphan, Laudicon,Opidol, Pal-
ladone, Hydromorph Contin). Since its clinical introduction in
1926, it has been used as an alternative opioid analgesic to mor-
phine, as it has a similar chemical structure but is more water sol-
uble (Urquhart 1988) and potent (Twycross 1994).
A range of issues relate to the use of hydromorphone in chronic
pain, including formulation, metabolism, potency compared with
other opioids, and risk of misuse (Gregory 2013). Most hydro-
morphone use has been for cancer pain, where advantages include
a range of possible routes of administration, together with an ab-
sence of active metabolites, differentiating hydromorphone from
morphine. Hydromorphone is itself an important metabolite of
hydrocodone.
Hydromorphone can be administered through oral (immedi-
ate- and controlled-release formulations), intravenous, subcuta-
neous, epidural, intrathecal, and other routes (Murray 2005). The
high aqueous solubility of hydromorphone is considered by some
healthcare professionals to be beneficial for people who are re-
sistant to opioids and require higher doses in cancer pain, often
administered by intrathecal pumps (Portenoy 2011). Hydromor-
phone as OROS® hydromorphone extended-release (ER) is five
times more potent than morphine (Binsfeld 2010; Sarhill 2001).
This allows a smaller milligram dose of hydromorphone to be used
for an equianalgesic effect.
How the intervention might work
Opioids such as hydromorphone bind to specific opioid receptors
in the nervous system and other tissues; there are three principal
classes of receptors (mu, kappa, and delta) though others have
been suggested, and subtypes of receptors are considered to exist.
Binding of opioid agonists such as hydromorphone to receptors
brings about complex cellular changes, outcomes of which include
decreased perception of pain, decreased reaction to pain, and in-
creased pain tolerance. Opioids from plant sources have been used
for thousands of years to treat pain.
Why it is important to do this review
One UK survey found that weak and strong opioids were used
frequently for treating neuropathic pain (Hall 2013). Hydromor-
phone is nowadays rarely prescribed. In the past, it was prescribed
either as the opioid of choice when morphine or other opioids
could not be tolerated, or when a higher dose of opioid was re-
quired. Since the early 2000s, a marked increase in prescribing of
opioids for non-cancer pain in general, despite a relatively modest
evidence base, has in some countries led to widespread diversion
with consequent abuse, misuse, and mortality. Concurrently, sus-
picion has arisen that opioid-induced hyperalgesia, together with
tolerance to the analgesic effects of opioids, may in reality result
in a lesser degree of benefit for opioids in neuropathic pain than
previously assumed.
The standards used to assess evidence in chronic pain trials have
changed substantially in recent years, with particular attention be-
ing paid to trial duration, withdrawals, and statistical imputation
following withdrawal, all of which can substantially alter estimates
of efficacy. The most important change is the move from using
mean pain scores, or mean change in pain scores, to the number
of people who have a large decrease in pain (by at least 50%) and
who continue in treatment, ideally in trials of eight to 12 weeks’
duration or longer. Pain intensity reduction of 50% or more cor-
relates with improvements in co-morbid symptoms, function, and
quality of life. These standards are set out in the PaPaS Author and
Referee Guidance for pain studies of the Cochrane Pain, Palliative
and Supportive Care Group (PaPaS 2012).
This Cochrane review assessed evidence using methods that make
both statistical and clinical sense, usingdeveloping criteria forwhat
constitutes reliable evidence in chronic pain (Moore 2010a). Trials
included and analysedmet aminimumof reporting quality (blind-
ing, randomisation), validity (duration, dose and timing, diagno-
sis, outcomes, etc), and size (ideally at least 500 participants in a
comparison in which the NNT is 4 or above; Moore 1998). This
approach sets high standards for the demonstration of efficacy and
marks a departure from how reviews were conducted previously.
Taking this newer, more rigorous approach is particularly impor-
tant for opioids in chronic non-cancer pain. Opioids in clinical
trials on non-cancer pain are associated with very high withdrawal
rates of up to 60% over about 12 weeks (Moore 2010b). Many
withdrawals occur within the first few weeks, when participants
experience pain relief but cannot tolerate the drug. The common
practice of using the last observed results carried forward to the
end of the trial many weeks later (last observation carried forward
(LOCF)) can, therefore, produce results based largely on partici-
pants no longer in the trial, and who in the real world could not
achieve pain relief because they could not take the drug. The newer
standards, outlined in Appendix 1, would not allow this and can
produce very different results. For example, one large analysis of
pooled data from trials in osteoarthritis and chronic low back pain
conducted over about 12 weeks judged oxycodone effective, but
an analysis of the same data using the new clinically meaningful
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standards showed it to be significantly worse than placebo (Lange
2010).
One previous Cochrane review demonstrated the limitations of
our knowledge about opioids in neuropathic pain, except in short
duration studies of 24 hours or less (McNicol 2013). These limi-
tations were confirmed by a review specific to oxycodone (Gaskell
2014). A review specific to hydromorphone is timely.
O B J E C T I V E S
To assess the analgesic efficacy of hydromorphone for chronic neu-
ropathic pain in adults, and the adverse events associated with its
use in clinical trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with double-
blind assessment of participant outcomes following two weeks or
more of treatment, although the emphasis of the review was on
studies with a duration of eight weeks or longer. We required full
journal publication, with the exception of online clinical trial re-
sults summaries of otherwise unpublished clinical trials and ab-
stracts with sufficient data for analysis. We did not include short
abstracts (usually meeting reports), or studies that were non-ran-
domised, studies of experimental pain, case reports, and clinical
observations.
Types of participants
Studies included adults aged 18 years and above with one or more
chronic neuropathic pain conditions including (but not limited
to):
1. cancer-related neuropathy;
2. central neuropathic pain;
3. complex regional pain syndrome (CRPS) Type II;
4. human immunodeficiency virus (HIV) neuropathy;
5. painful diabetic neuropathy (PDN);
6. phantom limb pain;
7. postherpetic neuralgia (PHN);
8. postoperative or traumatic neuropathic pain;
9. spinal cord injury; and
10. trigeminal neuralgia.
If studies included participants with more than one type of neuro-
pathic pain, we planned to analyse results according to the primary
condition.
Types of interventions
Hydromorphone at any dose, by any route, administered for the
relief of neuropathic pain and compared with placebo or any active
comparator.
Types of outcome measures
We anticipated that studies would use a variety of outcome mea-
sures, with most studies using standard subjective scales (numer-
ical rating scale (NRS) or visual analogue scale (VAS)) for pain
intensity or pain relief, or both. We were particularly interested
in Initiative on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) definitions for moderate and sub-
stantial benefit in chronic pain studies (Dworkin 2008). These are
defined as:
1. at least 30% pain relief over baseline (moderate);
2. at least 50% pain relief over baseline (substantial);
3. much or very much improved on Patient Global Impression
of Change scale (PGIC; moderate);
4. very much improved on PGIC (substantial).
These outcomes are different from those used in most earlier re-
views, concentrating as they do on dichotomous outcomes where
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50% pain intensity reduction, and ideally having no
worse than mild pain (Moore 2013b; O’Brien 2010).
Primary outcomes
1. Participant-reported pain relief of 30% or greater.
2. Participant-reported pain relief of 50% or greater.
3. PGIC much or very much improved.
4. PGIC very much improved.
Secondary outcomes
1. Any pain-related outcome indicating some improvement.
2. Withdrawals due to lack of efficacy, adverse events, and for
any cause.
3. Participants experiencing any adverse event.
4. Participants experiencing any serious adverse event. Serious
adverse events typically include any untoward medical
occurrence or effect that at any dose results in death, is life-
threatening, requires hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability or
incapacity, is a congenital anomaly or birth defect, is an
’important medical event’ that may jeopardise the person, or may
require an intervention to prevent one of the above
characteristics or consequences.
5. Specific adverse events, particularly somnolence and
dizziness.
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Search methods for identification of studies
Electronic searches
We searched the following databases, without language restric-
tions.
1. Cochrane Central Register of Controlled Trials
(CENTRAL, via the Cochrane Register of Studies Online
database (CRSO)) on 17 November 2015.
2. MEDLINE (via Ovid), 1946 to 17 November 2015.
3. EMBASE (via Ovid), 1974 to 17 November 2015.
Search strategies for CENTRAL, MEDLINE, and EMBASE are
in Appendix 2, Appendix 3, and Appendix 4, respectively.
Searching other resources
We reviewed the bibliographies of any RCTs identified and review
articles, and searched clinical trial databases (ClinicalTrials.gov (
ClinicalTrials.gov) and the World Health Organization Interna-
tional Clinical Trials Registry Platform (ICTRP) (apps.who.int/
trialsearch/)) to identify additional published or unpublished data.
We did not contact investigators or study sponsors.
Data collection and analysis
We planned to perform separate analyses according to particular
neuropathic pain conditions, and would combine different neuro-
pathic pain conditions in analyses for exploratory purposes only.
In the event, we included only one study, in people with chronic
low back pain with a neuropathic component.
Selection of studies
Wedetermined eligibility by first reading the abstract of each study
identified by the search. We eliminated studies that clearly did
not satisfy the inclusion criteria, and we obtained full copies of
the remaining studies. Two review authors made the decisions.
Two review authors read these studies independently and reached
agreement by discussion. We did not anonymise the studies in any
way before assessment. We provided a PRISMA flow chart (Figure
1).
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Figure 1. Study flow diagram.
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Data extraction and management
Two review authors extracted data independently using a standard
form and checked for agreement before entry into Review Man-
ager 5 (RevMan 2014), or any other analysis tool. We included
information about the pain condition and number of participants
treated, drug and dosing regimen, study design (placebo or active
control), study duration and follow-up, analgesic outcome mea-
sures and results, withdrawals, and adverse events (participants ex-
periencing any adverse event or serious adverse event).
Assessment of risk of bias in included studies
We used theOxfordQuality Score as the basis for inclusion (Jadad
1996), limiting inclusion to studies that were randomised and
double-blind as a minimum.
Two review authors independently assessed the risk of bias for each
study, using the criteria outlined in theCochraneHandbook for Sys-
tematic Reviews of Interventions (Higgins 2011), and adapted from
those used by the Cochrane Pregnancy and Childbirth Group,
with any disagreements resolved by discussion. We assessed the
following for each study.
1. Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, eg random number table; computer random number
generator); unclear risk of bias (when the method used to
generate the sequence was not clearly stated). We excluded
studies at a high risk of bias that used a non-random process (eg
odd or even date of birth; hospital or clinic record number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (eg telephone or central randomisation; consecutively
numbered, sealed, opaque envelopes); unclear risk of bias (when
the method was not clearly stated). We excluded studies that did
not conceal allocation and were therefore at a high risk of bias
(eg open list).
3. Blinding of outcome assessment (checking for possible
detection bias). We assessed the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed the methods as:
low risk of bias (study stated that it was blinded and described
the method used to achieve blinding, eg identical tablets,
matched in appearance and smell); unclear risk of bias (study
stated that it was blinded but did not provide an adequate
description of how it was achieved). We excluded studies at a
high risk of bias that were not double-blind.
4. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk of bias (fewer than 10% of
participants did not complete the study or used ’baseline
observation carried forward’ analysis, or both); unclear risk of
bias (used LOCF analysis); or high risk of bias (used ’completer’
analysis).
5. Size of study (checking for possible biases confounded by
small size). We assessed studies as being at low risk of bias (200
participants or more per treatment arm); unclear risk of bias (50
to 199 participants per treatment arm); or high risk of bias
(fewer than 50 participants per treatment arm).
Measures of treatment effect
We planned to calculate NNTs as the reciprocal of the absolute
risk reduction (ARR; McQuay 1998). For unwanted effects, the
NNTbecomes the number needed to treat for an additional harm-
ful outcome (NNH) and is calculated in the same manner. We
planned to use dichotomous data to calculate risk ratio (RR) with
95% confidence intervals (CI) using a fixed-effect model unless
we found significant statistical heterogeneity (see below). We did
not plan to use continuous data in analyses.
Unit of analysis issues
We planned to split the control treatment arm between active
treatment arms in a single study if there was more than one active
treatment arm, and they were not combined for analysis.
Dealing with missing data
We extracted data using intention-to-treat (ITT) analysis where
the ITT population consisted of participants who were ran-
domised, took at least one dose of the assigned study medication,
and provided at least one postbaseline assessment. We assigned
zero improvement to missing participants wherever possible.
Assessment of heterogeneity
Weplanned to deal with clinical heterogeneity by combining stud-
ies that examined similar conditions, and assess statistical hetero-
geneity visually (L’Abbé 1987), and with the use of the I2 statis-
tic. If the I2 value was greater than 50%, we planned to consider
possible reasons for this. In the event, there was only one included
study, so heterogeneity was not an issue.
11Hydromorphone for neuropathic pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of reporting biases
The aim of this reviewwas to use dichotomous outcomes of known
utility and of value to people with pain (Hoffman 2010; Moore
2010c; Moore 2010d; Moore 2010e; Moore 2013b). The review
did not depend on what the authors of the original studies chose to
report or not, though clearly difficulties arose because the included
study did not report any dichotomous efficacy results. Therefore,
we extracted mean data, which probably reflect efficacy and utility
poorly, as a secondary outcome that could give some indication of
efficacy.
We planned to assess publication bias using a method designed to
detect the amount of unpublished data with a null effect required
to make any result clinically irrelevant (usually taken to mean an
NNT of 10 or higher; Moore 2008). In the event, this was not
possible.
Data synthesis
We planned to use a fixed-effect model for meta-analysis, or a
random-effectsmodel if therewas significant clinical heterogeneity
and it was considered appropriate to combine studies.
We planned to analyse data for each painful condition in three
tiers, according to outcome and freedom from known sources of
bias.
1. The first tier would use data meeting current best standards,
where studies reported the outcome of at least 50% pain
intensity reduction over baseline (or its equivalent), without the
use of LOCF or other imputation method for drop-outs,
reported an ITT analysis, lasted eight or more weeks, had a
parallel-group design, and had at least 200 participants
(preferably at least 400) in the comparison (Moore 1998; Moore
2010a; Moore 2012a; Moore 2012b).
2. The second tier would use data from at least 200
participants but where one or more of the first-tier conditions
above was not met (eg reporting at least 30% pain intensity
reduction, using LOCF or a completer analysis, or lasting four to
eight weeks).
3. The third tier of evidence would relate to data from fewer
than 200 participants, or where there were expected to be
significant problems because, for example, of very short duration
studies of less than four weeks; where there was major
heterogeneity between studies; or where there were shortcomings
in allocation concealment, attrition, or incomplete outcome
data. For this third tier of evidence, no data synthesis is
reasonable and may be misleading, but an indication of
beneficial effects might be possible.
Quality of the evidence
Two review authors independently rated the quality of each out-
come. We used the GRADE (Grades of Recommendation, As-
sessment, Development and Evaluation) system to assess the qual-
ity of the evidence related to the key outcomes listed in Types
of outcome measures, as appropriate (Appendix 5; Chapter 12,
Higgins 2011).
’Summary of findings’ table
We have included a ’Summary of findings’ table as set out in the
author guide (PaPaS 2012). We have included the planned out-
comes of at least 50% pain intensity reduction and PGIC very
much improved (substantial benefit), at least 30% pain intensity
reduction and PGIC much or very much improved (moderate
benefit), withdrawals due to adverse events, serious adverse events,
and death. In addition, we have included ’lack of efficacy with-
drawal in randomised double-blind phase’, since this may be a
relevant indicator of efficacy for this study design.
Subgroup analysis and investigation of heterogeneity
We planned all analyses to be according to individual neuropathic
pain conditions, because placebo response rates for the same out-
come can vary between conditions, as can the drug-specific effects
(Moore 2009).
We did not plan subgroup analyses since experience of previous
reviews indicated that there would be too few data for any mean-
ingful subgroup analysis (Gaskell 2014; McNicol 2013).
Sensitivity analysis
We did not plan specific sensitivity analysis because the evidence
base is known to be too small to allow reliable analysis. We had
hoped to examine details of dose-escalation schedules to see if this
could provide some basis for a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
Our searches identified 22 potentially relevant records in CEN-
TRAL, 74 in MEDLINE, and 153 in EMBASE. We found one
additional study by searching the reference lists of published arti-
cles, but no further studies in clinical trial registries. After reading
the titles and abstracts, we obtained and read the full texts of seven
records. We included one study (four records) and excluded three
studies (Figure 1).
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Included studies
We included one study, which was reported in four publications.
Participants had moderate to severe chronic low back pain, and
results for participantswith a definite or probable neuropathic pain
component were reported separately from participants with non-
neuropathic or nociceptive pain in a post hoc analysis (Nalamachu
2014). The neuropathic component was determined using the
Quebec Task Force Classification of Spinal Disorders (Classes 3
to 6; QTFSD 1987). This record was one of four publications
between 2010 and 2014 reporting on the same clinical trial, but
as best we can judge none was a duplicated report.
Participants were opioid-tolerant and taking stable doses of anal-
gesics for at least two weeks before screening. The study had an
open-label conversion and titration period lasting two to four
weeks, followed by a randomised, double-blind, placebo-con-
trolled withdrawal period of 12 weeks for participants who had
a good response. These ’responders’ took 12 to 64 mg of hydro-
morphone ER daily at a stable dose for at least seven consecutive
days, had a mean pain intensity of 4/10 or less, required two or
fewer doses of rescue medication per day, had no intolerable ad-
verse events, and believed that the study medication had helped
their pain.
Overall, the study included equal numbers of men and women
with amean age of 49 years and baseline pain intensity at screening
of 6.4/10, and at randomisation of 3.2/10. A minority of partici-
pants were classified as having neuropathic pain. In the whole trial,
443 participants were screened initially, and 167 (38%) of them
were considered to have neuropathic pain. Of the 167, 73 (44%)
did not meet the criteria for entering the randomised, double-
blind comparison with placebo, and the final number entering the
randomised double-blind comparison between hydromorphone
and placebo was 94 (56%).
The study was not randomised according to neuropathic pain sta-
tus. While the numbers across groups appeared reasonably simi-
lar for most characteristics, the authors commented that the sub-
groups were not balanced.
Excluded studies
We excluded three studies because they recruited participants with
various pain conditions and did not report results for neuropathic
pain separately. In addition, one was open-label (Binsfeld 2010),
and two had double-blind treatment periods of seven days or less
(Grosset 2005; Jansen DO-119).
Risk of bias in included studies
A summary of the risk of bias assessment is available in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
The studywas randomised for the double-blindwithdrawal period
and themethodof randomisation and allocation concealmentwere
described. We judged this study at low risk of bias for random
sequence generation and allocation concealment.
Blinding
The study was blinded for the withdrawal period, and the method
of blinding was described. Participants allocated to the placebo
arm in this period had a tapered withdrawal of active treatment,
which should help to maintain blinding. We judged this study at
low risk of bias for performance and detection bias.
Incomplete outcome data
All participants were accounted for and imputation methods were
described. Different imputation methods were used according to
the reason for withdrawal. It is not immediately apparent that
this was appropriate, especially as LOCF was used for lack of
efficacy and other withdrawals not due to adverse events of opioid
withdrawal symptoms. We judged this study at unclear risk of bias
for attrition bias.
Selective reporting
We could not judge whether there was selective reporting as this
was a post hoc analysis, presumably performed after the blind was
broken, and was not the primary report of the study.
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Other potential sources of bias
We judged the study to be at high risk of bias due to its size (43
participants in the hydromorphone arm and 51 participants in the
placebo arm for the randomised phase).
Effects of interventions
See: Summary of findings for the main comparison Oral
hydromorphone compared with placebo for chronic neuropathic
pain
Since we identified only one study for inclusion, we were unable
to carry out any analyses. We judged the quality of the evidence as
very low, downgraded because there was only one study with few
participants, it did not report clinically useful efficacy outcomes,
and it was a post hoc analysis (Summary of findings for the main
comparison).
Efficacy
The included study used an enriched enrolment, randomisedwith-
drawal (EERW) design, so did not report any of our prespecified
efficacy outcomes. See Appendix 6 for summary of efficacy.
Of the 167 participants with neuropathic pain who entered the
conversion and titration phase, 94 (56%) were classified as ’re-
sponders’ (see Included studies: adequate pain control, stable dose
within predefined range, tolerable adverse events), and 44% with-
drew. The mean pain intensity was reduced from 6.4/10 to 3.2/
10, and the mean Patient Global Assessment of treatment was re-
duced from 3.7 to 2.6 (1 = excellent, 5 = poor).
Of the 43 participants with neuropathic pain randomised to con-
tinue with hydromorphone ER, 21 (49%) withdrew during the
double-blind withdrawal phase, compared with 30/51 (59%) who
were randomised to placebo. Withdrawal due to lack of efficacy in
the double-blind withdrawal phase occurred in 8/43 participants
with hydromorphone ER and 9/51 with placebo. The mean in-
crease in pain intensity during this period was 0.6/10 with hydro-
morphone ER and 1.4/10 with placebo.
Withdrawals
See Appendix 7 for summary of withdrawals.
Withdrawals due to lack of efficacy
In the conversion and titration phase, 27/167 (16%) participants
withdrew due to lack of efficacy.
In the double-blind withdrawal phase, withdrawals due to lack of
efficacy occurred in 8/43 participants with hydromorphone ER
and 9/51 with placebo.
Withdrawals due to adverse events
In the conversion and titration phase, 20/167 (12%) participants
withdrew due to adverse events.
In the double-blind withdrawal phase, withdrawals due to adverse
events occurred in 3/43 participants with hydromorphone ER and
0/51 with placebo. An additional participant taking hydromor-
phone ER and two taking placebo withdrew due to opioid with-
drawal symptoms.
Other withdrawals
In the conversion and titration phase, 15/167 (9%) participants
were withdrawn because of protocol violations and non-compli-
ance. In the double-blind withdrawal phase, 4/43 participants tak-
inghydromorphoneERand12/51 takingplacebowerewithdrawn
for the same reasons.
Adverse events
See Appendix 7 for summary of adverse events.
Any adverse event
During conversion and titration, 95/167 (57%) participants expe-
rienced adverse events. Most were of mild or moderate intensity,
and the most commonly reported events were constipation (22
participants) and nausea (15 participants).
During the double-blind withdrawal phase, 21/43 (49%) partic-
ipants experienced adverse events with hydromorphone ER and
27/51 (53%) with placebo. Once again, they were mostly mild or
moderate in intensity, and themost commonly reported eventwith
hydromorphone ER was constipation (five participants) and with
placebo was opioid withdrawal syndrome (seven participants).
Serious adverse events
There were no deaths during the study, and serious adverse events
were not reported for the neuropathic andnon-neuropathic groups
separately. In the original study report, which includedparticipants
with both neuropathic and non-neuropathic back pain, 6/447
participants evaluated for safety had serious adverse events during
the conversion and titrationphase, while 6/134 had serious adverse
events with hydromorphone ER and 4/134 with placebo in the
double-blindwithdrawal phase (Hale 2010, seeNalamachu 2014).
D I S C U S S I O N
Summary of main results
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We found only one post hoc analysis of a study assessing the ef-
ficacy of hydromorphone in neuropathic pain to include in this
review. The results showed a somewhat larger increase in average
pain intensity for placebo than for continuing with hydromor-
phone ER, but as well as an unusual study design there was an un-
usual choice of imputation methods for withdrawals (about 50%
of participants). Adverse events occurred in about half of partici-
pants with hydromorphone and the most common were constipa-
tion and nausea. A similar proportion of participants experienced
adverse events with placebo, and in this case the most common
was opioid withdrawal syndrome. Most adverse events were mild
or moderate in intensity, but a substantial number led to with-
drawal, particularly during the conversion and titration phase, de-
spite participants being opioid-tolerant (very low quality and in-
adequate evidence).
Overall completeness and applicability of
evidence
The amount of evidence we have is small, from one post hoc anal-
ysis, and limited to one type of neuropathic pain. While the par-
ticipants were classified as having chronic low back pain with a
definite or probable neuropathic component, the precise nature of
the neuropathy was not known and may further limit the general-
isability of the results. Participants were opioid-tolerant at screen-
ing, and it might be expected that withdrawals would be higher
in an unselected population.
There is insufficient evidence to consider how well hydromor-
phone works even in people with low back pain with a neuropathic
component, and these meagre results cannot be generalised to
other types of neuropathic pain. We found no information about
other routes of administration. Two open-label studies indicated
that analgesic efficacy might be possible in some people with neu-
ropathic pain over the longer term. One randomised open-label
comparison between hydromorphone and oxycodone ER formu-
lations in 112 participants had a 52 week follow-up, and showed
that reduced pain wasmaintained over that period (Richarz 2013).
One small open cohort (20 participants) also reported that pain
decreased in some participants over four weeks (Suzan 2013).
As best we know, there is no high-quality evidence to support or
refute the use of hydromorphone for treating neuropathic pain.
This is despite the fact that aUK survey found thatweak and strong
opioids were used frequently for treating neuropathic pain, either
alone or in combination with other drugs (Hall 2013). The lack of
high-quality evidence for long term benefit with hydromorphone
reflects a similar result with oxycodone, buprenorphine, and other
opioids (Gaskell 2014; McNicol 2013; Wiffen 2015). The lack of
evidence of efficacy combined with substantial evidence of harm
has led to calls for referral to a pain management specialist (ideally
with expertise in opioid use) if daily dosing exceeds 80 to 100 mg
morphine equivalents, particularly if pain and function are not
substantially improved (Franklin 2014).
Quality of the evidence
The study methods were fundamentally sound, but this was a post
hoc analysis, and the number of participants with neuropathic
painwas small (Moore 2015). The randomised double-blindwith-
drawal phase was underpowered, and did not have an outcome
related to a level of pain that participants might find acceptable
(Moore 2013b). For example, the ’loss of therapeutic response’
(’treatment failure’ in Hale 2010) is a typical outcome for EERW
trials (Moore 2015). Moreover, the one included study used three
different imputation methods for withdrawals, depending on rea-
son for withdrawal, and it was not clear how that might affect
the conclusions. Taken together, these factors downgraded the ev-
idence for all outcomes to very low quality, which means that fur-
ther research is very likely to have an important impact on our
confidence in our understanding of the effect.
Potential biases in the review process
We know of no potential biases in the review process. It is unlikely
that there is a large body of unpublished evidence showing a large
effect from hydromorphone in neuropathic pain.
Agreements and disagreements with other
studies or reviews
This review agrees with previous reviews and Cochrane reviews
that there appears to be no body of good clinical studies assessing
the efficacy of hydromorphone, at any dose or in any formulation,
for neuropathic pain (McNicol 2013). The one study in this review
was published after McNicol 2013.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with neuropathic pain
There is insufficient evidence to support or refute the suggestion
that hydromorphone has any efficacy in any neuropathic pain
condition.
For clinicians
There is insufficient evidence to support or refute the suggestion
that hydromorphone has any efficacy in any neuropathic pain
condition.
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For policy makers
There is insufficient evidence to support or refute the suggestion
that hydromorphone has any efficacy in any neuropathic pain
condition. In the absence of any supporting evidence, it should
probably not be recommended, except at the discretion of a pain
specialist with particular expertise in opioid use.
For funders
There is insufficient evidence to support or refute the suggestion
that hydromorphone has any efficacy in any neuropathic pain
condition. In the absence of any supporting evidence, it should
probably not be recommended, except at the discretion of a pain
specialist with particular expertise in opioid use.
Implications for research
Large, robust randomised trials with patient-centred outcomes
would be required to produce evidence to support or refute efficacy
of hydromorphone in neuropathic pain. The necessary design of
such trials is well established, but, for opioids in neuropathic pain,
the outcomes should be those of at least 30% and at least 50% pain
intensity reduction over baseline at the end of a trial of 12 weeks’
duration in participants continuing on treatment. Withdrawal for
any reason should be regarded as treatment failure, and last obser-
vation carried forward (LOCF) analysis should not be used. The
reason for this is that, in chronic pain, opioids frequently produce
withdrawal rates of 50% or more, meaning that LOCF analysis
can overstate treatment efficacy.
A C K N OW L E D G E M E N T S
Institutional supportwas provided by theOxfordPainRelief Trust.
The National Institute for Health Research (NIHR) is the largest
single funder of the Cochrane Pain, Palliative and Supportive Care
Review Group.
Disclaimer: the views and opinions expressed herein are those
of the review authors and do not necessarily reflect those of the
NIHR, National Health Service (NHS), or the Department of
Health.
The protocol followed the agreed template for neuropathic pain,
which was developed in collaboration with the Cochrane Muscu-
loskeletal Group and Cochrane Neuromuscular Diseases Group.
The editorial process was managed by the Cochrane Pain, Pallia-
tive and Supportive Care Group.
R E F E R E N C E S
References to studies included in this review
Nalamachu 2014 {published data only}
Hale M, Khan A, Kutch M, Li S. Once-daily OROS
hydromorphone ER compared with placebo in opioid-
tolerant patients with chronic low back pain. Current
Medical Research and Opinion 2010;26(6):1505–18. [DOI:
10.1185/03007995.2010.484723]
Hale ME, Nalamachu SR, Khan A, Kutch M. Effectiveness
and gastrointestinal tolerability during conversion and
titration with once-daily OROS® hydromorphone
extended release in opioid-tolerant patients with chronic
low back pain. Journal of Pain Research 2013;6:319–29.
[DOI: 10.2147/JPR.S39980]
Jamison RN, Edwards RR, Liu X, Ross EL, Michna
E, Warnick M, et al. Relationship of negative affect
and outcome of an opioid therapy trial among low back
pain patients. Pain Practice 2013;13(3):173–81. [DOI:
10.1111/j.1533-2500.2012.00575.x]
∗ Nalamachu S, Hale M, Khan A. Hydromorphone
extended release for neuropathic and non-neuropathic/
nociceptive chronic low back pain: a post hoc analysis of
data from a randomized, multicenter, double-blind, placebo-
controlled clinical trial. Journal of Opioid Management
2014;10(5):311–22. [DOI: 10.5055/jom.2014.0221]
References to studies excluded from this review
Binsfeld 2010 {published data only}
Binsfeld H, Szczepanski L, Waechter S, Richarz U,
Sabatowski R. A randomized study to demonstrate
noninferiority of once-daily OROS(®) hydromorphone
with twice-daily sustained-release oxycodone for moderate
to severe chronic noncancer pain. Pain Practice 2010;10(5):
404–15. [DOI: 10.1111/j.1533-2500.2009.00342.x]
Grosset 2005 {published data only}
Grosset AB, Roberts MS, Woodson ME, Shi M, Swanton
RE, Reder RF, et al. Comparative efficacy of oral
extended-release hydromorphone and immediate-release
hydromorphone in patients with persistent moderate to
severe pain: two randomized controlled trials. Journal of
Pain and Symptom Management 2005;29(6):584–94. [DOI:
10.1016/j.jpainsymman.2004.10.008]
Jansen DO-119 {published data only}
Janssen. Jurnista prolonged release tablets, 2012.
www.medsafe.govt.nz/profs/datasheet/j/jurnistatab.pdf
(accessed 26 November 2015).
Additional references
Bao 2014
Bao YJ, Hou W, Kong XK, Yang L, Jones K, Xia J, et
al. Hydromorphone for cancer pain. Cochrane Database
17Hydromorphone for neuropathic pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/
14651858.CD011108]
Baron 2012
Baron R, Wasner G, Binder A. Chronic pain: genes,
plasticity, and phenotypes. Lancet Neurology 2012;11(1):
19–21. [DOI: 10.1016/S1474-4422(11)70281-2]
Bouhassira 2008
Bouhassira D, Lantéri-Minet M, Attal N, Laurent B,
Touboul C. Prevalence of chronic pain with neuropathic
characteristics in the general population. Pain 2008;136(3):
380–7. [DOI: 10.1016/j.pain.2007.08.013]
Calvo 2012
Calvo M, Dawes JM, Bennett DL. The role of the
immune system in the generation of neuropathic pain.
Lancet Neurology 2012;11(7):629–42. [DOI: 10.1016/
S1474-4422(12)70134-5]
Demant 2014
Demant DT, Lund K, Vollert J, Maier C, Segerdahl
M, Finnerup NB, et al. The effect of oxcarbazepine in
peripheral neuropathic pain depends on pain phenotype: a
randomised, double-blind, placebo-controlled phenotype-
stratified study. Pain 2014;155(11):2263–73. [DOI:
10.1016/j.pain.2014.08.014]
Derry 2012
Derry S, Moore RA. Topical capsaicin (low concentration)
for chronic neuropathic pain in adults. Cochrane Database
of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/
14651858.CD010111]
Derry 2013
Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical
capsaicin (high concentration) for chronic neuropathic pain
in adults. Cochrane Database of Systematic Reviews 2013,
Issue 2. [DOI: 10.1002/14651858.CD007393.pub3]
Derry 2014
Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical
lidocaine for neuropathic pain in adults. Cochrane Database
of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/
14651858.CD010958.pub2]
Dworkin 2008
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland
CS, Farrar JT, et al. Interpreting the clinical importance
of treatment outcomes in chronic pain clinical trials:
IMMPACT recommendations. Journal of Pain 2008;9(2):
105–21. [DOI: 10.1016/j.jpain.2007.09.005]
Finnerup 2013
Finnerup NB, Scholz J, Attal N, Baron R, Haanpää M,
Hansson P, et al. Neuropathic pain needs systematic
classification. European Journal of Pain 2013;17(7):953–6.
[DOI: 10.1002/j.1532-2149.2012.00282.x]
Finnerup 2015
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron
R, Dworkin RH, et al. Pharmacotherapy for neuropathic
pain in adults: a systematic review and meta-analysis.
Lancet Neurology 2015;14(2):162–73. [DOI: 10.1016/
S1474-4422(14)70251-0]
Franklin 2014
Franklin GM, American Academy of Neurology. Opioids
for chronic noncancer pain: a position paper of the
American Academy of Neurology. Neurology 2014;83(14):
1277–84. [DOI: 10.1212/WNL.0000000000000839]
Gaskell 2014
Gaskell H, Moore RA, Derry, S, Stannard C. Oxycodone
for neuropathic pain and fibromyalgia in adults. Cochrane
Database of Systematic Reviews 2014, Issue 6. [DOI:
10.1002/14651858.CD010692.pub2]
GRADEpro GDT 2015 [Computer program]
McMaster University. GRADEpro Guideline Development
Tool. McMaster University, 2015.
Gregory 2013
Gregory TB. Hydromorphone: evolving to meet the
challenges of today’s health care environment. Clinical
Therapeutics 2013;35(12):2007–27. [DOI: 10.1016/
j.clinthera.2013.09.027]
Gustorff 2008
Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K,
Schwarz F, et al. Prevalence of self-reported neuropathic pain
and impact on quality of life: a prospective representative
survey. Acta Anaesthesiologica Scandinavica 2008;52(1):
132–6. [DOI: 10.1111/j.1399-6576.2007.01486.x]
Hall 2008
Hall GC, Carroll D, McQuay HJ. Primary care incidence
and treatment of four neuropathic pain conditions: a
descriptive study, 2002-2005. BMC Family Practice 2008;9:
26. [DOI: 10.1186/1471-2296-9-26]
Hall 2013
Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ.
An observational descriptive study of the epidemiology and
treatment of neuropathic pain in a UK general population.
BMC Family Practice 2013;14:28. [DOI: 10.1186/
1471-2296-14-28]
Helfert 2015
Helfert SM, Reimer M, Höper J, Baron R. Individualized
pharmacological treatment of neuropathic pain. Clinical
Pharmacology and Therapeutics 2015;97(2):135–42. [DOI:
10.1002/cpt.19]
Higgins 2011
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing
risk of bias in included studies. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Hoffman 2010
Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do
changes in pain severity levels correspond to changes in
health status and function in patients with painful diabetic
peripheral neuropathy?. Pain 2010;149(2):194–201.
[DOI: 10.1016/j.pain.2009.09.017]
18Hydromorphone for neuropathic pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jadad 1996
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds
DJ, Gavaghan DJ, et al. Assessing the quality of reports
of randomized clinical trials: is blinding necessary?
. Controlled Clinical Trials 1996;17(1):1–12. [DOI:
10.1016/0197-2456(95)00134-4]
Jensen 2011
Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD,
Rice AS, et al. A new definition of neuropathic pain.
Pain 2011; Vol. 152, issue 10:2204–5. [DOI: 10.1016/
j.pain.2011.06.017]
Kalso 2013
Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic
pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339]
Katusic 1991
Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland
LT. Epidemiology and clinical features of idiopathic
trigeminal neuralgia and glossopharyngeal neuralgia:
similarities and differences, Rochester, Minnesota, 1945-
1984. Neuroepidemiology 1991;10:276–81. [DOI:
10.1159/000110284]
Koopman 2009
Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin
CG, Sturkenboom MC. Incidence of facial pain in the
general population. Pain 2009;147(1-3):122–7. [DOI:
10.1016/j.pain.2009.08.023]
L’Abbé 1987
L’Abbé KA, Detsky AS, O’Rourke K. Meta-analysis in
clinical research. Annals of Internal Medicine 1987;107:
224–33.
Lange 2010
Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel
T, Ashworth J, et al. Efficacy and safety of tapentadol
prolonged release for chronic osteoarthritis pain and low
back pain. Advances in Therapy 2010;27(6):381–99. [DOI:
10.1007/s12325-010-0036-3]
Lunn 2014
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating
painful neuropathy, chronic pain or fibromyalgia. Cochrane
Database of Systematic Reviews 2014, Issue 1. [DOI:
10.1002/14651858.CD007115.pub3]
McNicol 2013
McNicol ED, Midbari A, Eisenberg E. Opioids for
neuropathic pain. Cochrane Database of Systematic Reviews
2013, Issue 8. [DOI: 10.1002/14651858.CD006146.pub2]
McQuay 1998
McQuay H, Moore R. An Evidence-Based Resource for Pain
Relief. Oxford: Oxford University Press, 1998. [ISBN:
0–19–263048–2]
McQuay 2007
McQuay HJ, Smith LA, Moore RA. Chronic pain. In:
Stevens A, Raftery J, Mant J, Simpson S editor(s). Health
Care Needs Assessment, 3rd Series. Oxford: Radcliffe
Publishing, 2007:519–99. [ISBN: 978–1–84619–063–6]
Moore 1998
Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay
HJ. Size is everything - large amounts of information are
needed to overcome random effects in estimating direction
and magnitude of treatment effects. Pain 1998;78(3):
209–16. [DOI: 10.1016/S0304-3959(98)00140-7]
Moore 2008
Moore RA, Barden J, Derry S, McQuay HJ. Managing
potential publication bias. In: McQuay HJ, Kalso E,
Moore RA editor(s). Systematic Reviews in Pain Research:
Methodology Refined. Seattle: IASP Press, 2008:15–24.
[ISBN: 978–0–931092–69–5]
Moore 2009
Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ.
Pregabalin for acute and chronic pain in adults. Cochrane
Database of Systematic Reviews 2009, Issue 3. [DOI:
10.1002/14651858.CD007076.pub2]
Moore 2010a
Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube
S, et al. “Evidence” in chronic pain - establishing best
practice in the reporting of systematic reviews. Pain 2010;
150(3):386–9. [DOI: 10.1016/j.pain.2010.05.011]
Moore 2010b
Moore RA, Straube S, Derry S, McQuay HJ. Chronic
low back pain analgesic studies - a methodological
minefield. Pain 2010;149(3):431–4. [DOI: 10.1016/
j.pain.2010.02.032]
Moore 2010c
Moore RA, Straube S, Paine J, Phillips CJ, Derry S,McQuay
HJ. Fibromyalgia: moderate and substantial pain intensity
reduction predicts improvement in other outcomes and
substantial quality of life gain. Pain 2010;149(2):360–4.
[DOI: 10.1016/j.pain.2010.02.039]
Moore 2010d
Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni
A. Numbers-needed-to-treat analyses - do timing, dropouts,
and outcome matter? Pooled analysis of two randomized,
placebo-controlled chronic low back pain trials. Pain 2010;
151(3):592–7. [DOI: 10.1016/j.pain.2010.07.013]
Moore 2010e
Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni
AR, Wang H. Responder analysis for pain relief and
numbers needed to treat in a meta-analysis of etoricoxib
osteoarthritis trials: bridging a gap between clinical trials
and clinical practice. Annals of the Rheumatic Diseases 2010;
69(2):374–9. [DOI: 10.1136/ard.2009.107805]
Moore 2011a
Moore RA, Straube S, Paine J, Derry S, McQuay HJ.
Minimum efficacy criteria for comparisons between
treatments using individual patient meta-analysis of acute
pain trials: examples of etoricoxib, paracetamol, ibuprofen,
and ibuprofen/paracetamol combinations after third molar
extraction. Pain 2011;152(5):982–9.
Moore 2011b
Moore RA, Mhuircheartaigh RJ, Derry S, McQuay
HJ. Mean analgesic consumption is inappropriate
19Hydromorphone for neuropathic pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
for testing analgesic efficacy in post-operative pain:
analysis and alternative suggestion. European Journal of
Anaesthesiology 2011;28(6):427–32. [DOI: 10.1097/
EJA.0b013e328343c569]
Moore 2012a
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ.
Amitriptyline for neuropathic pain and fibromyalgia in
adults. Cochrane Database of Systematic Reviews 2012, Issue
12. [DOI: 10.1002/14651858.CD008242.pub2]
Moore 2012b
Moore RA, Straube S, Eccleston C, Derry S, Aldington D,
Wiffen P, et al. Estimate at your peril: imputation methods
for patient withdrawal can bias efficacy outcomes in chronic
pain trials using responder analyses. Pain 2012;153(2):
265–8. [DOI: 10.1016/j.pain.2011.10.004]
Moore 2013a
Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic
failure; pursue analgesic success. BMJ 2013;346:f2690.
[DOI: 10.1136/bmj.f2690]
Moore 2013b
Moore RA, Straube S, Aldington D. Pain measures and
cut-offs - ’no worse than mild pain’ as a simple, universal
outcome. Anaesthesia 2013;68(4):400–12. [DOI: 10.1111/
anae.12148]
Moore 2014a
Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The
costs and consequences of adequately managed chronic non-
cancer pain and chronic neuropathic pain. Pain Practice
2014;14(1):79–94. [DOI: 10.1111/papr.12050]
Moore 2014b
Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin
for chronic neuropathic pain and fibromyalgia in adults.
Cochrane Database of Systematic Reviews 2014, Issue 4.
[DOI: 10.1002/14651858.CD007938.pub3]
Moore 2014c
Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine
use in chronic painful conditions - individual patient data
responder analysis. European Journal of Pain 2014;18(1):
67–75. [DOI: 10.1002/j.1532-2149.2013.00341.x]
Moore 2015
Moore RA, Wiffen PJ, Eccleston C, Derry S, Baron R,
Bell RF, et al. Systematic review of enriched enrolment,
randomised withdrawal trial designs in chronic pain: a new
framework for design and reporting. Pain 2015;156(8):
1382–95. [DOI: 10.1097/j.pain.0000000000000088]
Murray 2005
Murray A, Hagen NA. Hydromorphone. Journal of Pain
and Symptom Management 2005;29(5):57–66. [DOI:
10.1016/j.jpainsymman.2005.01.007]
NICE 2013
National Institute for Health and Care Excellence (NICE).
Neuropathic pain - pharmacological management: the
pharmacological management of neuropathic pain in adults
in non-specialist settings, 2013. www.nice.org.uk/guidance/
cg173 (accessed 19 October 2014).
O’Brien 2010
O’Brien EM, Staud RM, Hassinger AD, McCulloch RC,
Craggs JG, Atchison JW, et al. Patient-centered perspective
on treatment outcomes in chronic pain. PainMedicine 2010;
11(1):6–15. [DOI: 10.1111/j.1526-4637.2009.00685]
PaPaS 2012
Cochrane Pain, Palliative and Supportive Care Group
(PaPaS) author and referee guidance. papas.cochrane.org/
papas-documents (accessed 17 November 2015).
Portenoy 2011
Portenoy RK. Treatment of cancer pain. Lancet 2011;
377(9874):2236–47. [DOI: 10.1016/S0140-6736
(11)60236-5]
QTFSD 1987
Quebec Task Force on Spinal Disorders. Scientific approach
to the assessment and management of activity-related spinal
disorders. A monograph for clinicians. Spine (Phila Pa
1976) 1987;12 (7 Suppl):S1–59. [PUBMED: 2961086]
Rappaport 1994
Rappaport ZH, Devor M. Trigeminal neuralgia: the role of
self-sustaining discharge in the trigeminal ganglion. Pain
1994;56:127–38. [DOI: 10.1016/0304-3959(94)90086-8]
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Richarz 2013
Richarz U, Waechter S, Sabatowski R, Szczepanski
L, Binsfeld H. Sustained safety and efficacy of once-
daily hydromorphone extended-release (OROS®
hydromorphone ER) compared with twice-daily oxycodone
controlled-release over 52 weeks in patients with moderate
to severe chronic noncancer pain. Pain Practice 2013;13(1):
30–40. [DOI: 10.1111/j.1533-2500.2012.00553.x]
Sarhill 2001
Sarhill N, Walsh D, Nelson KA. Hydromorphone:
pharmacology and clinical applications in cancer patients.
Supportive Care in Cancer 2001;9(2):84–96. [DOI:
10.1007/s005200000183]
Straube 2008
Straube S, Derry S, McQuay HJ, Moore RA. Enriched
enrolment: definition and effects of enrichment and dose
in trials of pregabalin and gabapentin in neuropathic
pain. A systematic review. British Journal of Clinical
Pharmacology 2008;66(2):266–75. [DOI: 10.1111/
j.1365-2125.2008.03200]
Straube 2010
Straube S, Derry S, Moore RA, Paine J, McQuay HJ.
Pregabalin in fibromyalgia - responder analysis from
individual patient data. BMC Musculoskeletal Disorders
2010;11:150. [DOI: 10.1186/1471-2474-11-150]
Sultan 2008
Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine
for painful diabetic neuropathy and fibromyalgia pain:
20Hydromorphone for neuropathic pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
systematic review of randomised trials. BMC Neurology
2008;8:29. [DOI: 10.1186/1471-2377-8-9]
Suzan 2013
Suzan E, Eisenberg E, Treister R, Haddad M, Pud D. A
negative correlation between hyperalgesia and analgesia in
patients with chronic radicular pain: is hydromorphone
therapy a double-edged sword?. Pain Physician 2013;16(1):
65–76.
Torrance 2006
Torrance N, Smith BH, Bennett MI, Lee AJ. The
epidemiology of chronic pain of predominantly neuropathic
origin. Results from a general population survey.
Journal of Pain 2006;7(4):281–9. [DOI: 10.1016/
j.jpain.2005.11.008]
Treede 2008
Treede RD, Jensen TS, Campbell JN, Cruccu G,
Dostrovsky JO, Griffin JW, et al. Neuropathic pain:
redefinition and a grading system for clinical and research
purposes. Neurology 2008;70(18):1630–5. [DOI: 10.1212/
01.wnl.0000282763.29778.59]
Twycross 1994
Twycross RG. Pain Relief in Advanced Cancer. Singapore:
Churchill Livingstone, 1994:279.
Urquhart 1988
Urquhart ML, Klapp K, White PF. Patient-controlled
analgesia: a comparison of intravenous versus subcutaneous
hydromorphone. Anesthesiology 1988;69(3):428–32.
[PUBMED: 2458059]
van Hecke 2014
van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N.
Neuropathic pain in the general population: a systematic
review of epidemiological studies. Pain 2014;155(4):
654–62. [DOI: 10.1016/j.pain.2013.11.013]
von Hehn 2012
von Hehn CA, Baron R, Woolf CJ. Deconstructing
the neuropathic pain phenotype to reveal neural
mechanisms. Neuron 2012;73(4):638–52. [DOI: 10.1016/
j.neuron.2012.02.008]
Vos 2012
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud
C, Ezzati M, et al. Years lived with disability (YLDs) for
1160 sequelae of 289 diseases and injuries 1990-2010: a
systematic analysis for the Global Burden of Disease Study
2010. Lancet 2012;380(9859):2163–96. [DOI: 10.1016/
S0140-6736(12)61729-2]
Wiffen 2013
Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice
ASC, et al. Antiepileptic drugs for neuropathic pain and
fibromyalgia - an overview of Cochrane reviews. Cochrane
Database of Systematic Reviews 2013, Issue 11. [DOI:
10.1002/14651858.CD010567.pub2]
Wiffen 2015
Wiffen PJ, Derry S, Moore RA, Stannard C, Aldington
D, Cole P, et al. Buprenorphine for neuropathic pain in
adults. Cochrane Database of Systematic Reviews 2015, Issue
9. [DOI: 10.1002/14651858.CD011603.pub2]
References to other published versions of this review
Quigley 2013
Quigley C. Hydromorphone for acute and chronic pain.
Cochrane Database of Systematic Reviews 2013, Issue 10.
[DOI: 10.1002/14651858.CD003447.pub2]
∗ Indicates the major publication for the study
21Hydromorphone for neuropathic pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Nalamachu 2014
Methods Multicentre, double-blind, placebo-controlled study with open-label conversion and
titration phase (2 to 4 weeks), and randomised, double-blind, parallel-group withdrawal
phase (12 weeks) for ’responders’ (enriched enrolment, randomised withdrawal study).
Responders took 12 to 64 mg hydromorphone ER daily, with dose unchanged for ≥ 7
consecutive days, mean PI ≤ 4/10, required ≤ 2 tablets of rescue medication daily, had
no intolerable AEs, believed study medication had helped their pain
Participants Moderate to severe chronic LBP (classified as NP or non-NP), aged 18 to 75 years, taking
stable doses of any analgesics for ≥ 2 weeks
Excluded: other chronic pain condition, back surgery within 6 months, fibromyalgia,
CRPS, acute spinal cord compression, severe or progressive lower extremity weakness or
numbness, diskitis
N = 459 entered titration phase (443 took medication and had LBP classification), 267
entered randomised phase
In randomised phase
Mean age 49 (SD 11) years
M 133, F 134
NP LBP 94, non-NP LBP 173
PI at screening 6.4/10, at randomisation 3.2/10
Interventions Titration phase:
Starting dose of hydromorphone ER orally equivalent to 75% equianalgesic dose of
previous total daily opioid dose. Maximum dose 64 mg daily
Randomised withdrawal phase:
Hydromorphone ER orally, n = 134 (43 NP, 91 non-NP)
Placebo orally (tapered down over 2 weeks), n = 133 (51 NP, 83 non-NP)
Outcomes Responders during conversion and titration
Mean change in weekly PI over withdrawal phase, and both phases (scale 0 to 10)
PGA (1 to 5)
Use of rescue medication
AEs
Notes Oxford Quality Score: R2, DB2, W1. Total = 5/5
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated randomization
schedule”
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Nalamachu 2014 (Continued)
Allocation concealment (selection bias) Low risk “automated assignment of treat-
ment groups to randomization numbers”,
“interactive voice response system”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “matching placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “matching placebo”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imputation for withdrawals: BOCF for
opioid withdrawal symptoms; SOCF for
AEs; LOCF for lack of efficacy
Size High risk < 50 participants per treatment arm (43 to
51)
AE: adverse event; BOCF: baseline observation carried forward; CRPS: Chronic Regional Pain Syndrome; DB: double-blind; ER:
extended release; F: female; LBP: low back pain; LOCF: last observation carried forward; M: male; N: number of participants in
study; n: number of participants in treatment arm; NP: neuropathic pain; PGA: Patient Global Assessment; PI: pain intensity; R:
randomised; SD: standard deviation; SOCF: screening observation carried forward; W: withdrawals.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Binsfeld 2010 Open-label, mixed pain conditions (results not reported separately for neuropathic pain)
Grosset 2005 Mixed pain conditions (results not reported separately for neuropathic pain), double-blind treatment period only
3 to 7 days
Jansen DO-119 Non-malignant or cancer pain, randomised treatment lasted only 7 days
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 17 November 2015.
Date Event Description
13 June 2016 Amended Minor change to wording in Declarations of interest, for clarity.
C O N T R I B U T I O N S O F A U T H O R S
SD and RAM wrote the protocol.
SD, PW, and RAM searched for and selected studies for inclusion, and carried out data extraction.
All review authors were involved in writing the full review.
PW will be responsible for any updates required.
D E C L A R A T I O N S O F I N T E R E S T
CS: none known; CS is a specialist pain physician and manages patients with neuropathic pain.
HG: none known; HG is an Associate Specialist in Clinical Geratology.
SD: none known.
DA is a specialist pain physician and manages patients with neuropathic pain. He has received lecture fees from Grünenthal (2013,
2014, 2015) and Pfizer (2013, 2016).
PC is a specialist pain physician and manages patients with neuropathic pain. He has received support from Pfizer (2013) and Boston
Scientific (2014) for travel and accommodation at a scientific meeting.
TC: none known.
RK has consulted for Grünenthal (2014-15) and MundiPharma Research (2015), and received lecture fees from Grünenthal (2013-
14), and Pfizer Ltd (2013-14).
PW: none known.
RAM has received grant support from RB relating to individual patient level analyses of trial data on ibuprofen in acute pain and the
effects of food on drug absorption of analgesics (2013), and from Grünenthal relating to individual patient level analyses of trial data
regarding tapentadol in osteoarthritis and back pain (2015). He has received honoraria for attending boards with Menarini concerning
methods of analgesic trial design (2014), with Novartis (2014) about the design of network meta-analyses, and RB on understanding
pharmacokinetics of drug uptake (2015).
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S O U R C E S O F S U P P O R T
Internal sources
• Oxford Pain Relief Trust, UK.
General institutional support
External sources
• The National Institute for Health Research (NIHR), UK.
NIHR Cochrane Programme Grant: 13/89/29 - Addressing the unmet need of chronic pain: providing the evidence for treatments of
pain
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol included both complex regional pain syndrome (CRPS) I and CRPS II as a diagnosis of neuropathic pain. We have now
removed CRPS I because it is no longer considered to be neuropathic pain. There were no studies in CRPS I.
In the ’Summary of findings’ table, we included the outcome ’lack of efficacy withdrawal in randomised double-blind phase’, since this
may be a relevant indicator of efficacy for this enriched enrolment, randomised withdrawal study design.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesics, Opioid [∗therapeutic use]; Chronic Pain [∗drug therapy]; Hydromorphone [∗therapeutic use]; Neuralgia [∗drug therapy];
Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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